What is the primary goal of gene therapy?

The primary goal of gene therapy is to treat or prevent diseases by correcting or modifying the underlying genetic defects. Instead of just managing symptoms, it aims to address the root cause of the illness by introducing, removing, or altering genetic material within a patient's cells. This could involve replacing a faulty gene with a functional one, inactivating a gene that is causing harm, or introducing a new gene that provides a therapeutic benefit, such as making a protein to fight cancer or an infection.

What are vectors in gene therapy, and why are they important?

Vectors are essential delivery vehicles used in gene therapy to transport the therapeutic genetic material (DNA or RNA) into target cells. They are crucial because naked DNA or RNA cannot efficiently enter cells on its own and would be quickly degraded. Viruses, modified to be non-pathogenic, are the most common vectors due to their natural ability to infect cells and deliver their genetic payload. They ensure that the corrective gene reaches the specific cells where it needs to function, making the therapy effective.

Explain the difference between 'ex vivo' and 'in vivo' gene therapy.

'Ex vivo' gene therapy involves taking cells out of the patient's body, genetically modifying them in a laboratory setting (e.g., by introducing a new gene using a viral vector), and then reintroducing these modified cells back into the patient. This approach allows for greater control over the modification process. 'In vivo' gene therapy, on the other hand, involves directly administering the gene-carrying vector into the patient's body, where it targets and modifies cells within the body itself. This method is simpler but requires precise targeting and careful management of potential immune responses.

What is ADA deficiency, and how is gene therapy used to treat it?

ADA deficiency, or adenosine deaminase deficiency, is a genetic disorder that leads to severe combined immunodeficiency (SCID). Patients lack the enzyme adenosine deaminase, which is crucial for the development and function of lymphocytes (a type of white blood cell). Without ADA, toxic metabolites accumulate, destroying T and B lymphocytes, leaving the individual highly susceptible to infections. Gene therapy for ADA-SCID typically uses an ex vivo approach: lymphocytes are extracted from the patient, a functional ADA gene is introduced into them using a retroviral vector, and the corrected lymphocytes are then reinfused, restoring immune function.

What are the ethical concerns surrounding germline gene therapy?

Germline gene therapy involves modifying the genes in reproductive cells (sperm or egg) or early embryos, meaning the genetic changes would be heritable and passed on to future generations. This raises significant ethical concerns. These include the potential for unintended and irreversible changes to the human gene pool, the concept of 'designer babies' where genetic traits are selected for non-medical reasons, and the inability of future generations to consent to these genetic alterations. Due to these profound implications, germline gene therapy is currently not approved or practiced in humans.

Why are viruses commonly used as vectors in gene therapy?

Viruses are commonly used as vectors in gene therapy because they have evolved highly efficient mechanisms for entering host cells and delivering their genetic material. Scientists modify these viruses by removing their disease-causing genes and replacing them with the therapeutic gene. This leverages the virus's natural ability to infect cells and integrate or express its genetic payload, making them excellent tools for gene delivery. Different types of viruses, like retroviruses, adenoviruses, and adeno-associated viruses, are chosen based on their specific characteristics, such as their ability to infect dividing or non-dividing cells, their gene-carrying capacity, and their immunogenicity.

← ALL TOPICS

Biology

NEXT TOPIC →

Bt Cotton and Pest Resistant Plants

Gene Therapy

Biology

NEET UG

Version 1Updated 21 Mar 2026

Explore This Topic

Definition Deep Explanation Core Principles NEET Importance Problem Strategy Practice Problems MCQ Practice Quick Revision

Gene therapy represents a revolutionary biotechnological approach aimed at treating or preventing diseases by modifying a person's genes. This technique involves introducing new genetic material into a patient's cells to replace faulty genes, inactivate problematic genes, or introduce new genes that can help fight a disease. It holds immense promise for inherited disorders, certain types of cancer…

Quick Summary

Gene therapy is a revolutionary medical approach that aims to treat or prevent diseases by modifying a person's genetic material. It targets the root cause of genetic disorders, certain cancers, and infectious diseases.

The core principle involves introducing a functional gene, inactivating a problematic gene, or adding a new gene to cells. This genetic material is delivered using 'vectors,' most commonly modified viruses like retroviruses, adenoviruses, or adeno-associated viruses, which are engineered to carry the therapeutic gene without causing illness.

Gene therapy can be performed 'ex vivo,' where cells are modified outside the body and then reinfused, or 'in vivo,' where the vector is directly administered to the patient. A classic example is the treatment of severe combined immunodeficiency (SCID) caused by adenosine deaminase (ADA) deficiency, where a functional ADA gene is introduced into lymphocytes.

While somatic cell gene therapy (non-heritable changes) is in clinical use, germline gene therapy (heritable changes) raises significant ethical concerns and is not currently practiced.

Vyyuha

Your 6-Month Blueprint, Updated Nightly

AI analyses your progress every night. Wake up to a smarter plan. Every. Single.…

Key Concepts

Viral Vectors in Gene Therapy

Viral vectors are engineered viruses stripped of their pathogenic genes and loaded with therapeutic DNA.…

ADA-SCID Gene Therapy Mechanism

Severe Combined Immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency is a classic example of…

Somatic vs. Germline Gene Therapy

This distinction is crucial for understanding the ethical landscape of gene therapy. Somatic cell gene…

Gene Therapy: — Modifying genes to treat disease.

Goal: — Replace faulty genes, inactivate problematic genes, introduce new therapeutic genes.

Vectors: — Delivery vehicles for genes. Primarily modified viruses (Retrovirus, Adenovirus, AAV).

Retrovirus: — Integrates, long-term, dividing cells only, risk of insertional mutagenesis.

Adenovirus: — Episomal, transient, dividing & non-dividing, strong immune response.

AAV: — Mostly episomal, long-term, dividing & non-dividing, low immunogenicity (popular).

Ex vivo: — Cells modified outside body, then reinfused (e.g., ADA-SCID).

In vivo: — Vector directly administered into body.

Somatic Cell GT: — Non-heritable, clinically accepted.

Germline GT: — Heritable, ethically prohibited.

ADA-SCID: — Classic example. Deficiency of Adenosine Deaminase enzyme. Treated by ex vivo gene therapy using retroviral vector to introduce functional ADA gene into lymphocytes.

VECTORS: Viruses Enter Cells To Offer Remedial Solutions.

ADA-SCID: All Deficient Antibodies Stop Combating Infections Due to Defective ADA gene. (Gene therapy is the fix!)

← ALL TOPICS

Biology

NEXT TOPIC →

Bt Cotton and Pest Resistant Plants